What is DiaMedica Therapeutics Inc.'s (DMAC) StockRank?

MoatMap's StockRank for DiaMedica Therapeutics Inc. (DMAC) is 10/100, with a Strong Sell signal. This is a composite score combining Quality (36), Value (34), and Momentum (23) factor ranks across MoatMap's 19,000+ stock universe.

Does DiaMedica Therapeutics Inc. have an economic moat?

DiaMedica Therapeutics Inc. (DMAC) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is DiaMedica Therapeutics Inc. a buy, hold, or sell?

MoatMap's current signal for DiaMedica Therapeutics Inc. (DMAC) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is DiaMedica Therapeutics Inc. in?

DiaMedica Therapeutics Inc. (DMAC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DMAC

STRONG SELLREMOVE

DiaMedica Therapeutics Inc. · Healthcare · United States · $332M · Avg Vol: $963K/d

StockRank

P/E (TTM)

—

ROE

-86.5%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company. It lacks commercialized products and predictable cash flows, making it a speculative binary bet rather than a quality compounder.

COMPANY DESCRIPTION

DiaMedica Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel recombinant proteins for the treatment of kidney disease and neurological disorders. The company's lead candidate, DM199, is a recombinant form of human kallikrein-1, which targets multiple pathways involved in organ damage and inflammation. DiaMedica's competitive position is centered on its proprietary therapeutic approach to conditions with significant unmet medical need.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.52	-0.60	-0.60	-0.70	—
Shares	26M	38M	43M	54M	+103.2%
Debt	469,000	400,000	340,000	240,000	-20.0%
Equity	32M	51M	41M	56M	20.8%
Op CF	-12M	-19M	-22M	-29M	—
Inv CF	12M	-18M	9M	-2M	—
Fin CF	-6,000	37M	12M	44M	—

PRICE (1M)-6.9%

SMA 50SMA 200

$5.63

RSI (14)

31.1

52W High

$10.42

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-61.2%10.7

ROE

-86.5%9.2

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-29.3%10.2

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.00x93.4

Current Ratio

9.11x85.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-6.9x76.8

P/FCF

—N/A

P/B

6.4x18.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

54%29.0

RS 6M

-48%22.9

SMA 50/200

0.85x22.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-24%13.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$332M

P/E (Forward)

-6.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMAC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DMAC	DiaMedica Therapeutics Inc.(you)	$332M	10	STRONG SELL
NMRA	Neumora Therapeutics, Inc.	$348M	10	STRONG SELL
IVVD	Invivyd, Inc.	$333M	9	STRONG SELL
CMPX	Compass Therapeutics, Inc.	$348M	8	STRONG SELL
LYEL	Lyell Immunopharma, Inc.	$393M	8	STRONG SELL
FBRX	Forte Biosciences, Inc.	$425M	10	STRONG SELL
IMRX	Immuneering Corporation	$327M	16	STRONG SELL
LXEO	Lexeo Therapeutics, Inc.	$399M	7	STRONG SELL
TRDA	Entrada Therapeutics, Inc.	$265M	13	STRONG SELL
LENZ	LENZ Therapeutics, Inc.	$251M	7	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

DiaMedica Therapeutics Inc. (DMAC) — Stock Score Summary

DiaMedica Therapeutics Inc. (DMAC) has a MoatMap StockRank of 10/100 based on Quality (36/100), Value (34/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. DiaMedica Therapeutics is a clinical-stage biopharmaceutical company. It lacks commercialized products and predictable cash flows, making it a speculative binary bet rather than a quality compounder.

Key Financial Metrics

Price	$5.63
Market Cap	$332M
P/E (Forward)	-6.42
Price/Book	6.44
Return on Equity	-86.5%
Return on Invested Capital	-61.2%
Debt/Equity	0.45
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-18M

DiaMedica Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is DiaMedica Therapeutics Inc.’s (DMAC) StockRank?: MoatMap’s StockRank for DiaMedica Therapeutics Inc. (DMAC) is 10/100, with a Strong Sell signal. It is a composite of Quality (36), Value (34), and Momentum (23) factor ranks across MoatMap’s 19,000+ stock universe.
Does DiaMedica Therapeutics Inc. have an economic moat?: DiaMedica Therapeutics Inc. (DMAC) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is DiaMedica Therapeutics Inc. a buy, hold, or sell?: MoatMap’s current signal for DiaMedica Therapeutics Inc. (DMAC) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is DiaMedica Therapeutics Inc. in?: DiaMedica Therapeutics Inc. (DMAC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).